0001193125-20-148768.txt : 20200521 0001193125-20-148768.hdr.sgml : 20200521 20200521164906 ACCESSION NUMBER: 0001193125-20-148768 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200521 DATE AS OF CHANGE: 20200521 EFFECTIVENESS DATE: 20200521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allergan Funding SCS CENTRAL INDEX KEY: 0001620554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981177603 STATE OF INCORPORATION: N4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36886 FILM NUMBER: 20902516 BUSINESS ADDRESS: STREET 1: 6, RUE JEAN MONNET CITY: LUXEMBOURG STATE: N4 ZIP: L-2180 BUSINESS PHONE: (862) 261-7000 MAIL ADDRESS: STREET 1: 6, RUE JEAN MONNET CITY: LUXEMBOURG STATE: N4 ZIP: L-2180 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Funding SCS DATE OF NAME CHANGE: 20140925 15-12B 1 d934278d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Numbers:  

001-36886

333-223089-02

333-202168-02

333-199019-03

 

 

Allergan Funding SCS

(as Issuer)

(Exact name of registrant as specified in its charter)

 

 

Allergan Funding SCS

2, Rue Joseph Hackin

L-1746 Luxembourg

Grand Duchy of Luxembourg

+352 42 7171 3254

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Floating Rate notes due 2020

0.500% notes due 2021

3.450% notes due 2022

1.500% notes due 2023

1.250% notes due 2024

3.850% notes due 2024

3.800% notes due 2025

2.625% notes due 2028

2.125% notes due 2029

4.550% notes due 2035

4.850% notes due 2044

4.750% notes due 2045

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1)   ☒   
  Rule 12g-4(a)(2)   ☐   
  Rule 12h-3(b)(1)(i)   ☒   
  Rule 12h-3(b)(1)(ii)   ☐   
  Rule 15d-6   ☐   
  Rule 15d-22(b)   ☐   

Approximate number of holders of record as of the certification or notice date:

Floating Rate notes due 2020: Less than 300 holders

0.500% notes due 2021: Less than 300 holders

3.450% notes due 2022: Less than 300 holders

1.500% notes due 2023: Less than 300 holders

1.250% notes due 2024: Less than 300 holders

3.850% notes due 2024: Less than 300 holders

3.800% notes due 2025: Less than 300 holders

2.625% notes due 2028: Less than 300 holders

2.125% notes due 2029: Less than 300 holders

4.550% notes due 2035: Less than 300 holders

4.850% notes due 2044: Less than 300 holders

4.750% notes due 2045: Less than 300 holders

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Allergan Funding SCS has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: May 21, 2020     Allergan Funding SCS
    By:  

/s/ Pradipto Bagchi

    Name:   Pradipto Bagchi
    Title:   Class A Manager
    By:  

/s/ Severine Lucie Canova

    Name:   Severine Lucie Canova
    Title:   Class B Manager